A T Pavia1, M Benyo, L Niler, I Risk. 1. Bureau of HIV/AIDS Prevention and Control, Utah Department of Health, Salt Lake City.
Abstract
OBJECTIVES: We sought to evaluate the utility of partner notification for control of human immunodeficiency virus (HIV) infection and to identify subgroups in which it may be most effective. METHODS: All persons reported to be HIV-positive during a 2-year period were interviewed. Outcome measures included proportion of index patients cooperating; number of partners named, located, counseled, and tested; number of persons newly testing positive; and costs. RESULTS: Of 308 index patients, 244 (79%) cooperated. They named 890 partners; 499 (70%) of in-state partners were located. Of these, 154 (34%) had previously tested HIV-positive. Of 279 partners tested for the first time, 39 (14%) were HIV-positive. Injecting drug users were significantly more likely to cooperate than persons in other risk groups (93% vs 76%) and named more partners (median 4 vs 1). Women and persons choosing confidential testing were more likely to cooperate and named more partners. The estimated cost of the program was $62,500 per year. CONCLUSIONS: Partner notification identified a group with a high seroprevalence of HIV. It was not successful among populations that may be difficult to reach with other interventions.
OBJECTIVES: We sought to evaluate the utility of partner notification for control of human immunodeficiency virus (HIV) infection and to identify subgroups in which it may be most effective. METHODS: All persons reported to be HIV-positive during a 2-year period were interviewed. Outcome measures included proportion of index patients cooperating; number of partners named, located, counseled, and tested; number of persons newly testing positive; and costs. RESULTS: Of 308 index patients, 244 (79%) cooperated. They named 890 partners; 499 (70%) of in-state partners were located. Of these, 154 (34%) had previously tested HIV-positive. Of 279 partners tested for the first time, 39 (14%) were HIV-positive. Injecting drug users were significantly more likely to cooperate than persons in other risk groups (93% vs 76%) and named more partners (median 4 vs 1). Women and persons choosing confidential testing were more likely to cooperate and named more partners. The estimated cost of the program was $62,500 per year. CONCLUSIONS: Partner notification identified a group with a high seroprevalence of HIV. It was not successful among populations that may be difficult to reach with other interventions.
Authors: J K Andrus; D W Fleming; D R Harger; M Y Chin; D V Bennett; J M Horan; G Oxman; B Olson; L R Foster Journal: Ann Intern Med Date: 1990-04-01 Impact factor: 25.391
Authors: R F Wykoff; C W Heath; S L Hollis; S T Leonard; C B Quiller; J L Jones; M Artzrouni; R L Parker Journal: JAMA Date: 1988-06-24 Impact factor: 56.272
Authors: R F Wykoff; J L Jones; S T Longshore; S L Hollis; C B Quiller; H Dowda; W B Gamble Journal: Sex Transm Dis Date: 1991 Oct-Dec Impact factor: 2.830
Authors: Jacob J van den Berg; Marjan Javanbakht; Pamina M Gorbach; Bret J Rudy; Andrew O Westfall; Craig M Wilson; Michelle A Lally Journal: J Acquir Immune Defic Syndr Date: 2018-01-01 Impact factor: 3.731
Authors: Matthew J Mimiaga; Sari L Reisner; Ashley M Tetu; Katherine E Bonafide; Kevin Cranston; Thomas Bertrand; David S Novak; Kenneth H Mayer Journal: Public Health Rep Date: 2009 Jan-Feb Impact factor: 2.792
Authors: Elin B Begley; Alexandra M Oster; Binwei Song; Linda Lesondak; Kelly Voorhees; Magdalena Esquivel; Ronald L Merrick; Jack Carrel; Douglas Sebesta; James Vergeront; Dhana Shrestha; James D Heffelfinger Journal: Public Health Rep Date: 2008 Nov-Dec Impact factor: 2.792
Authors: Ram K Shrestha; Hollie A Clark; Stephanie L Sansom; Binwei Song; Holly Buckendahl; Cindy B Calhoun; Angela B Hutchinson; James D Heffelfinger Journal: Public Health Rep Date: 2008 Nov-Dec Impact factor: 2.792
Authors: Nyikadzino Mahachi; Auxilia Muchedzi; Taurayi A Tafuma; Peter Mawora; Liz Kariuki; Bazghina-Werq Semo; Moses H Bateganya; Tendai Nyagura; Getrude Ncube; Mike B Merrigan; Otto N Chabikuli; Mulamuli Mpofu Journal: J Int AIDS Soc Date: 2019-07 Impact factor: 5.396